Takeda Launches Adynovate To Advance Prophylaxis Treatment For Hemophilia Patients in India
An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII, providing excellent prophylactic coverage · Adynovate in combination with MYPKFIT®offers personalized treatment and enables HCPs and…









